ATE187966T1 - 4-(1h-2-methylimidazo (4,5-c> pyridinylmethyl) phenylsulfonamidderivate als paf antagonisten - Google Patents
4-(1h-2-methylimidazo (4,5-c> pyridinylmethyl) phenylsulfonamidderivate als paf antagonistenInfo
- Publication number
- ATE187966T1 ATE187966T1 AT93903261T AT93903261T ATE187966T1 AT E187966 T1 ATE187966 T1 AT E187966T1 AT 93903261 T AT93903261 T AT 93903261T AT 93903261 T AT93903261 T AT 93903261T AT E187966 T1 ATE187966 T1 AT E187966T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- present
- general formula
- compounds
- directed
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 title 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 abstract 3
- 108010003541 Platelet Activating Factor Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929202791A GB9202791D0 (en) | 1992-02-11 | 1992-02-11 | Compounds |
| PCT/GB1993/000273 WO1993016075A1 (en) | 1992-02-11 | 1993-02-10 | 4-(1H-2-METHYLIMIDAZO[4,5-c]PYRIDINYLMETHYL)PHENYLSULPHONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE187966T1 true ATE187966T1 (de) | 2000-01-15 |
Family
ID=10710127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93903261T ATE187966T1 (de) | 1992-02-11 | 1993-02-10 | 4-(1h-2-methylimidazo (4,5-c> pyridinylmethyl) phenylsulfonamidderivate als paf antagonisten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5516783A (de) |
| EP (1) | EP0635018B1 (de) |
| JP (1) | JPH07503954A (de) |
| AT (1) | ATE187966T1 (de) |
| AU (1) | AU662208B2 (de) |
| CA (1) | CA2129898A1 (de) |
| DE (1) | DE69327394T2 (de) |
| ES (1) | ES2142861T3 (de) |
| GB (1) | GB9202791D0 (de) |
| WO (1) | WO1993016075A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434151A (en) * | 1992-08-24 | 1995-07-18 | Cytomed, Inc. | Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase |
| PT650485E (pt) | 1992-07-13 | 2001-03-30 | Millennium Pharm Inc | 2,5-diaril-tetra-hidro-tiofenos -furanos e analogos para o tratamento de desordens inflamatorias e imunitarias |
| US5463083A (en) * | 1992-07-13 | 1995-10-31 | Cytomed, Inc. | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| US5703093A (en) * | 1995-05-31 | 1997-12-30 | Cytomed, Inc. | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| US6201016B1 (en) | 1994-06-27 | 2001-03-13 | Cytomed Incorporated | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| US5750565A (en) * | 1995-05-25 | 1998-05-12 | Cytomed, Inc. | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| US5792776A (en) * | 1994-06-27 | 1998-08-11 | Cytomed, Inc., | Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders |
| GB9508748D0 (en) * | 1995-04-28 | 1995-06-14 | British Biotech Pharm | Benzimidazole derivatives |
| DK0790998T3 (da) * | 1995-09-08 | 2001-02-05 | Uriach & Cia Sa J | Azo-derivater af 5-aminosalicylsyre til behandling af inflammatorisk tarmsygdom |
| UA78537C2 (en) * | 2001-12-20 | 2007-04-10 | Bristol Myers Squibb Co | Derivatives of ?-(n-sulfonamido)acetamide as beta-amiloid inhibitors |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| GB0320983D0 (en) * | 2003-09-08 | 2003-10-08 | Biofocus Plc | Compound libraries |
| RU2383536C2 (ru) * | 2004-08-04 | 2010-03-10 | Тайсо Фармасьютикал Ко., Лтд. | Производное триазола |
| US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
| JP2008545801A (ja) * | 2005-06-10 | 2008-12-18 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | スルホンアミド化合物およびその使用 |
| US8022091B2 (en) * | 2006-02-03 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd. | Triazole derivative |
| RU2395499C2 (ru) * | 2006-02-06 | 2010-07-27 | Тайсо Фармасьютикал Ко., Лтд. | Ингибитор связывания сфингозин-1-фосфата |
| DK2177512T3 (da) * | 2007-08-01 | 2012-06-18 | Taisho Pharmaceutical Co Ltd | S1P1-bindingshæmmer |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| US8093276B2 (en) * | 2007-10-31 | 2012-01-10 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| WO2009112523A1 (en) * | 2008-03-14 | 2009-09-17 | Basf Se | Substituted pyraz inylmethyl sulfonamides for use as. fungicides |
| US20110059940A1 (en) * | 2008-05-08 | 2011-03-10 | Bristol- Myers Squibb Company | 2-Aryl Glycinamide Derivatives |
| US8044077B2 (en) * | 2009-03-19 | 2011-10-25 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production |
| US20110071199A1 (en) * | 2009-03-20 | 2011-03-24 | Bristol-Myers Squibb Company | Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease |
| US7977362B2 (en) * | 2009-03-20 | 2011-07-12 | Bristol-Myers Squibb Company | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives |
| TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| DK2935303T3 (da) | 2012-12-21 | 2021-05-03 | Janssen Biopharma Inc | 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV |
| GB201321735D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN117120444A (zh) | 2021-04-16 | 2023-11-24 | 吉利德科学公司 | 使用酰胺制备卡巴核苷的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804658A (en) * | 1986-09-15 | 1989-02-14 | G. D. Searle & Co. | Imidazopyridine derivatives and pharmaceutical compositions |
| PT98674B (pt) * | 1990-08-15 | 1999-01-29 | British Bio Technology | Processo para a preparacao de compostos que sao antagonistas do factor de activacao de plaquetas por exemplo derivados de imidazole e de seus intermedriarios |
| PT98673B (pt) * | 1990-08-15 | 1999-01-29 | British Bio Technology | Processo para a preparacao de compostos que sao antagonistas do factor de activacao de plaquetas por exemplo derivados de benzimidazole e de seus intermediarios |
| GB9107398D0 (en) * | 1991-04-09 | 1991-05-22 | British Bio Technology | Compounds |
| GB9116056D0 (en) * | 1991-07-24 | 1991-09-11 | British Bio Technology | Compounds |
| GB9200209D0 (en) * | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
-
1992
- 1992-02-11 GB GB929202791A patent/GB9202791D0/en active Pending
-
1993
- 1993-02-10 DE DE69327394T patent/DE69327394T2/de not_active Expired - Fee Related
- 1993-02-10 US US08/284,570 patent/US5516783A/en not_active Expired - Fee Related
- 1993-02-10 ES ES93903261T patent/ES2142861T3/es not_active Expired - Lifetime
- 1993-02-10 JP JP5513899A patent/JPH07503954A/ja active Pending
- 1993-02-10 AU AU34599/93A patent/AU662208B2/en not_active Ceased
- 1993-02-10 AT AT93903261T patent/ATE187966T1/de not_active IP Right Cessation
- 1993-02-10 WO PCT/GB1993/000273 patent/WO1993016075A1/en active IP Right Grant
- 1993-02-10 CA CA002129898A patent/CA2129898A1/en not_active Abandoned
- 1993-02-10 EP EP93903261A patent/EP0635018B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07503954A (ja) | 1995-04-27 |
| CA2129898A1 (en) | 1993-08-12 |
| US5516783A (en) | 1996-05-14 |
| EP0635018A1 (de) | 1995-01-25 |
| WO1993016075A1 (en) | 1993-08-19 |
| DE69327394T2 (de) | 2000-06-29 |
| AU3459993A (en) | 1993-09-03 |
| EP0635018B1 (de) | 1999-12-22 |
| AU662208B2 (en) | 1995-08-24 |
| DE69327394D1 (de) | 2000-01-27 |
| GB9202791D0 (en) | 1992-03-25 |
| ES2142861T3 (es) | 2000-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE187966T1 (de) | 4-(1h-2-methylimidazo (4,5-c> pyridinylmethyl) phenylsulfonamidderivate als paf antagonisten | |
| HU9303145D0 (en) | Process for producing of fibrinogen receptor antagonist compounds and pharmaceutical compositions containing them as medical agent | |
| ES2137998T3 (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
| HUP9802323A2 (hu) | Pirimidinszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyászati készítmények | |
| DE59402222D1 (de) | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel | |
| KR920008026A (ko) | 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물 | |
| HUP0002272A2 (hu) | Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| YU85001A (sh) | Derivati 5-fenil-pirimidina | |
| DK0738269T3 (da) | Piperidinderivater med PAF-antagonistaktivitet | |
| MD523G2 (ro) | Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin | |
| DK408987D0 (da) | Phenoxyeddikesyrederivater samt fremstilling deraf | |
| HUP0003577A2 (hu) | Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| ATE169217T1 (de) | Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten | |
| GR3032950T3 (en) | Substituted fused and bridged bicyclic compounds as therapeutic agents | |
| NO170580C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater | |
| DE69226703D1 (de) | Imidazo (4,5-c)pyridinderivate als paf antagonisten | |
| MD553G2 (ro) | Derivaţi noi ai pirazolopirimidinelor, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice care le conţin | |
| ATE18761T1 (de) | Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen. | |
| NZ225528A (en) | Benzimidazoles substituted in the 2 position by n(4-n-guanidyl) piperidinyl radicals; preparations thereof; pharmaceutical compositions | |
| NO170974C (no) | Analogifremgangsmaate for fremstilling av terapeutisk brukbare ((((3-pyridinyl)metylen)amino)oksy)alkansyrer og estere derav samt mellomprodukt for anvendelse ved fremgangsmaaten | |
| FR2658190B1 (fr) | Esters d'aminoacides de l'hydroquinone, leur procede de preparation et compositions pharmaceutiques ou cosmetiques les contenant. | |
| EP0277348A3 (de) | Imidazol- und Triazolderivate zur Verwendung als antimykotische Mittel | |
| BR9815690A (pt) | Composto, processo para a preparação de qualquer um dos compostos, composição farmacêutica, e, uso do composto de 3-(nafter-1-il-óxi) - pirrolidina, 3-(5,6,7,8 - tetraidro-nafterc-1-il-óxi) - pirrolindina | |
| UA27738C2 (uk) | 2,3,4,5,6,7-гексагідро-1-[4-[1-[4-(2метоксифеніл)піперазиніл]]-2-фенілбутирил]-1н-азепін або його фармацевтично прийнятна кислотно-адитивна сіль, що мають властивість пов'язувати рецептор 5нт1а, спосіб (варіанти) їх одержання, фармацевтична композиція | |
| ES2032312T3 (es) | 5-fenil-1,2,3a,4,5,9b-hexahidro-3h-ben(e)indoles, su obtencion y empleo como medicamentos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |